

## Genomic Vision strengthens its management team

**Bagneux (France) - Genomic Vision (FR0011799907 – GV / PEA-PME eligible)**, a molecular diagnostics company that specializes in the development of diagnostic tests for genetic diseases and cancers using the DNA molecular combing process, today announces that it is strengthening its management team through the appointment of three directors for its Business Development, Bio-informatics / Information Technology and Human Resources units.

These appointments are being carried out within the framework of Genomic Vision's development strategy, as presented at the time of the Company's IPO on the Euronext market in Paris in April 2014.

### **Henri ALLAIN is appointed Head of Business Development**

With a Research Masters degree from Paris 7 University, Henri ALLAIN (43) has close to 20 years of experience in strategic positions in medical sector companies and institutions. Prior to joining Genomic Vision, Henri ALLAIN was Strategic Marketing Director at e(ye)BRAIN (2009-2013), a company specializing in the diagnosis of neurological diseases through the study of ocular movements. Before that, he was Business Development Manager at Enterprise Ireland, an Irish governmental agency (2006-2009), and at Transgene, Member of the Institut Mérieux group (2002-2005). Between 2000 and 2002, he was Business Development Manager within the Technology Transfer Department at the Institut Pasteur. At Genomic Vision, his role will be to identify new collaboration opportunities with a view to developing the product pipeline and the technological platform.

### **Ivan KYRGYZOV is appointed Head of Bio-informatics and IT**

With a PhD. from the *Ecole Nationale Supérieure des Télécommunications* (TELECOM ParisTech), the author of numerous scientific publications and the owner of a patent in imaging, Ivan KYRGYZOV (32) has developed a number of innovative projects within companies such as ALTEN (European leader in Technology Consulting and Engineering) and EOS Imaging (pioneer in Orthopedic 2D/3D Imaging). Prior to joining Genomic Vision, Ivan KYRGYZOV spent four years as R&D Algorithmic Manager at Biospacelab, a company specializing in molecular imaging for life sciences. Helped by his multi-sectoral experience, Ivan KYRGYZOV will be in charge of the team of engineers responsible for automating and integrating the molecular combing platform.

### **Marie GORDIEN is appointed Head of Human Resources**

With two Research Masters degrees in Law (from Paris 1 Panthéon-Sorbonne and Paris 2 Panthéon-Assas Universities), Marie GORDIEN (40) has over 15 years of experience in Human Resources. In her career, she held a number of executive positions within subsidiaries and spinoffs of the Lafarge group (1998-2008). From 2008 to 2011, she was Head of Human Resources for Supply Chain France at Materis Paints, part of the Wendel group. Marie GORDIEN

is joining Genomic Vision after having been Head of HR for the subsidiaries of KEOLIS, a major public transport company. She will be in charge of strengthening the Company's HR policy during its growth phase.

**Aaron Bensimon, Genomic Vision's co-founder and Chairman, says:** *"We are delighted to welcome Marie, Henri and Ivan into our managerial team. Their expertise in their respective fields will be a major asset for Genomic Vision's development. We are convinced that, thanks to their contribution, we will be able to deploy our growth strategy even more effectively."*



## ABOUT GENOMIC VISION

A spinoff of the Institut Pasteur, Genomic Vision is a molecular diagnostics company specialized in developing diagnostic tests for genetic diseases and cancers. Using "molecular combing", an innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. Having benefited from the financial support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and Quest Diagnostics, the Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France.

## ABOUT MOLECULAR COMBING

DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed", and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient's genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to [www.genomicvision.com](http://www.genomicvision.com)

## CONTACT

### Genomic Vision

Aaron Bensimon  
Co-founder, Chairman & CEO  
Tel.: +33 1 49 08 07 50  
[investisseurs@genomicvision.com](mailto:investisseurs@genomicvision.com)

### NewCap

Investor Relations / Strategic Communications  
Dušan Orešanský / Emmanuel Huynh  
Tel.: +33 1 44 71 94 92  
[gv@newcap.fr](mailto:gv@newcap.fr)



## DISCLAIMER

*This press release contains certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.*

*This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.*